Research progress in the development of ncRNA-targeted drug scaffolds
10.3969/j.issn.1004-8812.2025.01.004
- VernacularTitle:非编码RNA靶点药物支架开发研究进展
- Author:
Wen-chao DOU
1
;
Yu PENG
;
Zheng ZHANG
Author Information
1. 兰州大学第一临床医学院,甘肃兰州 730000
- Publication Type:Journal Article
- Keywords:
Percutaneous coronary intervention;
In-stent restenosis;
Non-coding RNA drug scaffolds;
Vascular smooth muscle cells;
Endothelial cells;
Thrombosis
- From:
Chinese Journal of Interventional Cardiology
2025;33(1):42-46
- CountryChina
- Language:Chinese
-
Abstract:
Percutaneous coronary intervention(PCI)is the main treatment for coronary heart disease(CHD).is characterized by progressive lumen stenosis in the stent,which is related to the effect of PCI on vascular inflammation,platelet activation,smooth muscle cell proliferation and migration,and extracellular matrix remodeling caused by vascular mechanical injury.Endothelial cell(EC)growth can heal the vascular lining damaged by the stent and prevent thrombosis,while drug eluting stent(DES)implantation inhibits the proliferation of vascular smooth muscle cells(VSMC)while inhibiting the growth of all cells at the target lesion.At present,some studies have shown that some drugs developed around non-coding RNA and related epigenetic pathways can target and inhibit VSMC proliferation through scaffold delivery,without affecting vascular intimal reendothelialization and promoting vascular intimal healing.Therefore,this review reviews the research progress of non-coding RNA drug scaffolds development and related clinical trials to determine their feasibility in solving the problems related to the clinical application of DES.
